<DOC>
	<DOC>NCT00775411</DOC>
	<brief_summary>The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.</brief_summary>
	<brief_title>Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>50 years of age or older with active subfoveal choroidal neovascularization (CNV) secondary to AMD Central retinal thickness ≥ 300 µm Visual acuity between 20/400 and 20/32 Eligible for AntiVEGF therapy Previous treatment for CNV due to AMD High eye pressure Glaucoma Uncontrolled systemic disease Known allergy to the study medications Recent eye surgery or injections in the eye Female subjects that are of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>